Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
BPC-157 is a lab-made peptide, a chain of 15 amino acids, promoted online for healing tendons, muscles and the gut. In animal studies, most of them from one research group, it has protected the gut from injury and helped severed tendons heal in rodents; that is the strongest thing the evidence supports. In people the evidence nearly stops: about 88 people given it across every published report (five of them in a 2026 pilot whose registration could not be found), no controlled trial showing a benefit, and no published study of BPC-157 given on its own under the skin, or of the capsules, nasal sprays and daily microgram doses people ask about.
This review labels each finding by where it comes from: tested in people, reported in people, animal studies, lab studies or theory. It is part of the peptide library on our Peptide Therapy page, which explains how these reviews are made. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval.
- Evidence in people
- About 88 people given it: two controlled trials, four uncontrolled reports, five in one unblinded pilot. No benefit shown.
- The claim you’ve heard
- Heals tendons: not tested in people. Heals the gut: the one trial, in colitis, did not show a benefit.
- Doses tested in people
- Enemas, IV infusion, and knee, bladder or mouth injections. Under the skin: only five people, with a second peptide.
- Sport
- Prohibited at all times. WADA names BPC-157 in class S0 on its 2026 and 2027 Lists.
What BPC-157 is
BPC stands for “body protection compound.” Its developers at the University of Zagreb first made it in the early 1990s and describe it as a fragment of a larger protein from human stomach juice; whether the fragment itself occurs in the body rests on their own reports. In the trials below it was called PL 14736 (the enemas) and Bepecin (the 2015 tablets).
Two forms are in use, the plain peptide (free base) and its acetate salt, and the name is loose: the FDA reports finding different salts, derivatives and even different active substances “sold commercially under the same common name.” The FDA also notes that BPC-157 is sold in the United States in dietary supplement capsules and tablets; we found no FDA ruling on whether it can be a dietary ingredient.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: BPC-157 is not approved by the FDA. HHS, the federal department the FDA belongs to, says in a draft policy that it does not intend to act against compounding (making a medicine to order for one patient) of single-ingredient BPC-157 acetate in four dosage forms, under its conditions; that is not approval, and the FDA’s own staff recommended against listing BPC-157 for compounding, though HHS says the advisory committee voted in favor.
As of November 19, 2026, BPC-157 is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient BPC-157 acetate (subcutaneous, intramuscular, oral or topical) for a patient-specific prescription when the policy’s conditions are met; HHS’s notice says the policy “is not binding on HHS or the public”, and it is not FDA approval. The FDA’s own review proposed that BPC-157 “NOT be included” on that list; HHS says the advisory committee “voted in favor of inclusion”.
The FDA’s own review
The FDA’s staff proposed against listing because both forms “are not well characterized,” there is “a lack of information on the safety profile and immunogenicity risks” (immunogenicity: an unwanted immune response), and there is “insufficient evidence to make a conclusion on the effectiveness” for ulcerative colitis, the only use the FDA evaluated and one that already has FDA-approved drugs. BPC-157 also has no official monograph and is in no FDA-approved drug; of an ingredient in that position the FDA’s guidance says it “cannot be used in compounding” under section 503A and that a drug made from it “is not eligible for the exemptions in section 503A and may violate the FD&C Act” (the Federal Food, Drug, and Cosmetic Act). The FDA has published no minutes of the advisory committee’s July 2026 meeting.
HHS’s draft policy
HHS states its intention for cases “when all of the following circumstances are present.” For BPC-157 they include:
- the acetate form, in “subcutaneous, intramuscular, oral, and topical dosage forms” (under the skin, into a muscle, by mouth, on the skin; not a nasal spray);
- for an oral form, documentation “confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans” (bioavailability: how much of a dose reaches the blood);
- an ingredient from an FDA-registered manufacturer with a certificate of analysis, and the label statement “This is a compounded drug product. Not for resale.”
Neither HHS document gives an effective date. The policy does not change section 503A, does not mention section 503B (outsourcing facilities) and is not a statement about state pharmacy rules.
Kansas
A Kansas rule, K.A.R. 68-13-3(d), says a pharmacist “shall not compound a nonsterile preparation” (one taken by mouth or put on the skin) by “compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs,” and it reaches preparations shipped into Kansas. The Kansas Board of Pharmacy has published nothing in its guidance documents on how it applies the rule to BPC-157.
Warning letters
Before this policy, the FDA named BPC-157 in at least five warning letters: three to compounders (2019 to 2021) and two to sellers (2020 and 2023).
Sport
The World Anti-Doping Agency (WADA) names BPC-157 in class S0 of its Prohibited List (non-approved substances), prohibited at all times, on the 2026 List and on the 2027 List in force from January 1, 2027.
Claims you’ll see, and why sources disagree
A page that says BPC-157 heals and a page that says nothing is known are usually describing the same studies. Three things explain it:
- Which studies get counted. PubMed lists 239 records on BPC-157; a 2026 systematic review of the human evidence found three studies with 30 people and rated its certainty “very low.”
- Who is reading. The developers’ 2025 review reads the one controlled trial of benefit in people as positive; the FDA’s figures do not.
- Animal results read as human results. The tendon, gut, brain and pain claims rest on rodent and cell studies, and even journal reviews contain errors (the table’s last row).
| Claim | Level of evidence | Verdict |
|---|---|---|
| Heals tendons, ligaments, muscle and bone faster | Animal and lab studies, mostly from one group. Reported in people: one uncontrolled knee report. | Not tested in people with objective measures. |
| Heals the gut: IBS, “leaky gut,” ulcers, Crohn’s disease, colitis | Animal studies. Tested in people: one small enema trial in ulcerative colitis. | The trial did not show a difference from placebo. Other conditions: not tested in people. |
| Works by mouth | Animal studies. “Stable in stomach juice” traces to one 1995 meeting abstract, and surviving the stomach is not absorption. | Not tested in people with published results. |
| Safe, with rare and mild side effects | Tested and reported in people: about 88 people given it (five in the 2026 pilot), most followed for days to weeks. | Not established. What is accurate: no serious adverse event was reported in those studies, which are too few, small and short to show safety. |
| Relieves pain and inflammation | Animal studies: a short-lived effect in one rat pain model. Reported in people: uncontrolled reports only. | Not tested in a controlled study in people. |
| Protects the brain | Animal studies only. | Not tested in people. |
| Not on WADA’s Prohibited List | Stated in one 2025 journal review. | Contradicted: WADA names BPC-157 in class S0. |
“Not tested in people” is not “doesn’t work.” It cuts both ways: not shown to help, and not shown to be safe.
What the evidence consists of
The FDA’s own search, through December 2025, found five clinical studies. Ours, of PubMed and ClinicalTrials.gov on November 18, 2026, added one case series, and a 2026 pilot that neither database holds was found later (described under Dosing).
Tested in people: two enema trials
| Study | People | Design | What happened | Funding |
|---|---|---|---|---|
| Veljaca and colleagues, 2002 and 2003 | 32 healthy men; 24 received BPC-157 | Placebo-controlled phase 1 of a rectal enema | Adverse events much as with placebo (see Safety) | PLIVA’s drug program; funding statement not seen |
| Ruenzi and colleagues, 2005 | 53 adults with mild-to-moderate ulcerative colitis; 46 completed | Randomized, double-blind phase 2 of a daily enema | The disease score fell 3.2 points with BPC-157 (95% confidence interval -5.58 to -0.82) and 1.6 with placebo (-3.86 to 0.67); the difference was not statistically significant. | As above |
Both trials are known only from meeting abstracts, and the figures are the FDA’s reading of them. In the colitis trial the 95% confidence interval for the difference between the groups, -4.84 to 1.62 points, includes zero: the result is compatible with a benefit, with no difference, and with placebo doing better. The FDA’s account does not define the score or give the size of each group. The developers’ 2025 review says “Unlike the placebo, BPC 157 induced a statistically significant decrease” in the score; that is the change inside the BPC-157 group, not the comparison with placebo.
Reported in people: four uncontrolled reports
| Report | People | What was given | What was reported | Limits |
|---|---|---|---|---|
| Lee and Padgett, 2021 | 16 adults with knee pain | Injection into the knee joint; four also received thymosin beta-4 | 14 of 16 reported relief when phoned 6 to 12 months later | No measuring tool; done at the first author’s clinic |
| Lee, Walker and Ayadi, 2024 | 12 women with interstitial cystitis (bladder pain) | Injections into the bladder wall | 10 of 12 reported complete relief of symptoms | One overall rating; done at a private clinic |
| Lee and Burgess, 2025 | 2 adults who had received IV BPC-157 before | IV infusion | No change in organ blood tests; no side effects reported | Two people, three days |
| Froum and colleagues, 2026 | 3 adults with nerve injury after dental surgery | Injections in the mouth, with four other drugs | Near-complete return of sensation in all three | Five drugs at once; the authors: “causality cannot be established” |
None of the four had a comparison group, and the reported benefits are patients’ own ratings at clinics that offer the treatment, so they cannot separate the peptide from placebo, natural recovery or other treatments given with it. The first three come from one Florida physician at two clinics; their funding statements are behind a paywall. The knee report’s abstract says 11 of the 12 people given BPC-157 alone “had significant improvement”; a 2025 systematic review reads the same study as “7 of 12 patients reported relief for >6 months.” No study in people has measured tendon, ligament, muscle or gut healing with objective tests.
Animal studies
In the FDA’s summary, rodent studies report that BPC-157 prevents injury to the gut, heart and blood vessels, protects the kidneys, promotes healing of severed tendons, and protects nerve tissue in models of stroke and spinal cord injury. Three limits apply:
- No dose-response. The key experiments use the same two doses, a thousand-fold apart, and the FDA found that “A dose-response relationship could not be established” (more drug, more effect).
- Treatment at the time of injury. The peptide was mostly given before the injury or straight after it, with short follow-up.
- Few independent checks, and weaker ones. In the one independent tendon study, in rats in 2026, BPC-157 alone did not reach statistical significance on tendon strength or tissue scores; TB-500, tested beside it, did on both. We found no blinded, independent repeat of the developers’ main injury experiments.
Lab studies and how it is thought to work
The FDA’s statement comes first: “the molecular targets for BPC-157 have not been identified and its mechanisms of action remain poorly understood” (in plain terms, nobody knows what it acts on in the body). The leading proposals, none tested in people:
- New blood vessels (animal and lab studies). In rats, chick embryos and human blood-vessel cells in a dish, BPC-157 increased vessel growth. A 2026 paper from the Xi’an group (below) traces this to a protein, BACH1, that it keeps from being broken down.
- Nitric oxide (lab studies). In rings of human artery from 12 bypass-surgery donors, tested outside the body, it relaxed the vessel through a nitric oxide pathway.
Who produced the research
Of the 239 PubMed records, 177 (74%) list P. Sikirić or S. Seiwerth of the University of Zagreb as an author; leaving out reviews, comments, letters and editorials, 141 of 177 (80%) do. Sikirić is a named inventor on BPC patents dating from 1989 and 1997, and the group’s 2025 review states, “The authors declare no conflicts of interest.” One group with no Zagreb author, at a military medical university in Xi’an, China, did the safety, blood-level and BACH1 studies cited on this page; it is developing its own BPC-157 injection and holds a synthesis patent, and its papers declare no competing interests.
A record that comes mostly from one group, reports benefit across so many organs and injuries, and shows no dose-response between doses a thousand-fold apart is itself a reason for caution.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No study has compared the effect of one dose with another in people, so no dose can be called optimal.
Doses tested in people
| Study | People | Dose | Route | How often and how long |
|---|---|---|---|---|
| Veljaca, 2002 and 2003 | 24 healthy men | 0.25 to 2 mg per kg of body weight | Rectal enema | Once, then daily for 7 days |
| Ruenzi, 2005 | About 26 adults | 80 mg | Rectal enema | Daily for 2 weeks |
| Lee and Padgett, 2021 | 16 adults | 2 to 4 mg | Into the knee joint | 1 or 2 injections |
| Lee, Walker and Ayadi, 2024 | 12 women | 10 mg (1 mg at 10 sites) | Into the bladder wall | Once |
| Lee and Burgess, 2025 | 2 adults | 10 mg, then 20 mg | Into a vein, over 1 hour | Two days in a row |
| Froum, 2026 | 3 adults | 1 mg, with four other drugs | Under the lining of the mouth | Weekly for 4 weeks |
| Majumdar, 2026 | 5 adults | 0.8 mg, with thymosin beta-4 | Under the skin | Weekly for 26 weeks |
The last row needs care. All ten adults in that pilot had a spinal cord injury and intensive rehabilitation; five also received BPC-157 and a second peptide, which its article calls thymosin beta-4. Nobody was assigned at random or blinded, and there was no placebo. Its cited registration could not be found, its funding line is an unfilled template (“Funding: To be declared”), a company is thanked for “providing peptide materials”, its abstract and table disagree on injection-site reactions, and PubMed does not index its journal. It reported higher leg motor scores in the treated five; its authors call that “not evidence of efficacy”. It does not show that BPC-157 under the skin works or is safe at any dose.
No published human study has tested BPC-157 alone under the skin, the daily microgram amounts in common use, or any dose into a muscle or on the skin. The two studies by mouth have reported no results, and we found no nasal study in people or animals.
Doses in common use
These are amounts in circulation, reported so that you can see where each comes from; no trial set any of them.
- 200 to 500 micrograms under the skin, for four to eight weeks. Printed on seven commercial pages (clinic, pharmacy, physician, telehealth, seller and health-testing sites): a day’s amount on some, each of one or two daily injections on others; upper figures reach 600 to 1,000 micrograms a day, courses 12 or 16 weeks, breaks two weeks to two months. Among the 2,158 users who stated a dose in posts a preprint analysed, the median was 366 micrograms per injection. Not studied: the only study under the skin gave 0.8 mg once a week, with a second peptide.
- 1 mg to 20 mg a week under the skin or into a muscle, in two or three injections. A seller’s page quoted in a 2023 FDA warning letter. Not studied; the top of that range equals the 20 mg given once into a vein to two people.
- Capsules of 500 micrograms (also 250 micrograms and 1 mg), once or twice a day. Listed in the FDA’s record of the two withdrawn nominations and of products it found on sale, and on clinic, telehealth and supplement-seller pages; one gives 1.5 mg a day as the “Maximum commonly used”, while a compounding pharmacy’s product page lists strengths and says “We don’t recommend doses.” No study by mouth has reported results.
- By nose, 200 to 500 micrograms “per session”, once or twice daily; into a muscle, 250 to 500 micrograms once daily. An online protocol site and a clinic blog. Not studied in people by either route.
Seven of the pages read concede that no dose is established, approved or known for people; five print amounts all the same.
What the pharmacology supports, and what it doesn’t
- Route: measured in animals, and in people only after enemas. In the Xi’an group’s rats and dogs the half-life in blood was under 30 minutes (5.3 minutes in dogs, 15.2 in rats after an IV dose), and from an injection into a muscle about 14% to 19% of the dose reached the blood in rats and 45% to 51% in dogs; no published study has measured this under the skin or by mouth in any species. In people the only measurements followed enemas, which put the peptide straight into the colon: little or none was found in the blood.
- Claimed, not confirmed. A 2026 review says a two-person IV study measured a half-life under 30 minutes in people; that study’s abstract and the FDA’s summary of it mention no such measurement. A physician’s website says an injection near the injury “delivers the highest local concentration”; nothing has been measured after an injection under the skin in any species.
- Frequency: inferred. If people clear it as fast as rats and dogs do, a once-daily injection would leave no measurable peptide in the blood for most of the day; yet the animal effects were reported with once-daily dosing, so blood level may not be what matters. Whether the timing of doses matters is unknown.
- Duration and monitoring: convention. No study in people tested any length of use, cycle or break; what a prescriber would monitor is our Medical Director’s to set out.
- Amount: nothing measured. In the key animal experiments no dose-response could be established (above), and nobody knows whether any dose works in people, or what that dose would be.
What common protocols get wrong
- A rat dose scaled to a person and presented as research. A telehealth platform’s dosing article calls the common range “The most commonly referenced BPC-157 dose in research” and reaches it by scaling a rat dose; the publisher’s own corrected article says its earlier figures “came from peptide-vendor blogs, not from clinical research”.
- Citations that don’t hold up. Four of that article’s five references match no PubMed record as written, including its basis for saying a 2020 systematic review “confirmed that no significant adverse effects were reported in any published BPC-157 study”; nor does PubMed list the 2016 paper it credits with “reliable dose-response relationships”.
- One route’s numbers used for another. The publisher’s “research report” says injection under the skin “delivers bioavailability in the 14-51% range”: those are the rat and dog figures for injection into a muscle, as the same page says further down. Other pages print absorption percentages with no source.
- A reason for “cycling” with nothing behind it. A clinic’s protocol page says “continuous stimulation of the same receptor pathways can lead to reduced sensitivity over time”, although no receptor for BPC-157 is known.
- A safety claim resting on two people. The nasal protocol site says a double dose “is not dangerous”, citing human IV doses up to 20 mg; its link leads to the two-person, three-day IV study in the evidence above.
The dose, like the decision to use BPC-157 at all, is the prescriber’s to make for one patient.
Safety, and who should be most cautious
In the studies. In the phase 1 trial the most frequent adverse events, headache and flatulence, showed no obvious difference from placebo. In the colitis trial, three people on BPC-157 and two on placebo withdrew because of adverse events, mainly worsening colitis, and the authors reported no difference from placebo. The four uncontrolled reports recorded no adverse events; of the studies it reviewed, the FDA notes that “the authors provided limited information on safety and associated safety monitoring.” The 2026 pilot described under Dosing reported no serious adverse events in its five treated people, but did record injection-site redness, itching or lumps, brief lightheadedness, headache and one temporary rise in a liver enzyme. Long-term use has barely been studied: the longest published exposure is that pilot’s 26 weekly injections in five people, and before it four weekly doses or two weeks of daily enemas.
Outside the studies. In the FDA’s own count, its adverse-event database held three reports through December 4, 2025, all with injected products: nine days of redness and swelling at the injection site in a woman also using compounded thymosin; shortness of breath that led to an emergency-room visit in a man using compounded BPC-157 acetate; and darkening of the skin and gums that returned when a “research purposes only” BPC-157 and TB-500 product was restarted. Its food and supplement complaint system held three more cases, all with multi-ingredient supplements. The public version of the adverse-event database, as last updated on October 28, 2026, held 26 reports naming BPC-157, 12 of them (the FDA’s three included) listing it as a suspect product. All are raw reports as people and companies sent them in: in the FDA’s words, “there is no certainty that the reported adverse event was due to the suspect product”, and a count of reports says nothing about how often an event happens. The developers’ own 1997 patent says that giving “BPC peptides,” in particular by injection, “causes pain and/or necrosis” (tissue death), and it does not exempt the acetate form; that is a patent’s statement, not a study finding.
The FDA’s concerns. “There is insufficient clinical safety information to characterize the safety profile” of either form, and for injected and nasal use “BPC-157 may pose a significant risk for immunogenicity.”
Animal safety studies. The Xi’an group gave BPC-157 into the muscle of rats and dogs for up to 28 days and called it “well tolerated.” In the same data the FDA found “clinically relevant safety signals”: a clotting test (aPTT) that shortened in rats and lengthened in dogs, and raised levels of a liver enzyme (ALT), glucose and triglycerides. It was not mutagenic (no gene damage) in three tests. There is no full reproductive study, no study of whether it can cause cancer, and no animal safety study by mouth, under the skin or by nose.
The cancer question (theory). If you have cancer or have had it, this is the main reason for caution: a theoretical risk, with no evidence of harm and none of safety. BPC-157 promotes the growth of new blood vessels in animal and lab studies, and tumors need new vessels to grow, which is why a 2025 review calls this “a plausible tumor-promoting hazard.” In other research BACH1, the protein that BPC-157 protects, drove the spread of lung cancer in mice and the growth of tumor blood vessels. We found no published study designed to test whether BPC-157 changes tumor growth or spread in an animal with cancer. The developers claim “prominent anti-tumor potential,” citing a meeting abstract, a personal communication and one mouse study in which the difference was not statistically significant.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy or breastfeeding | Not studied in people; registered trials exclude both | One rat study found no malformations; no fertility, birth or nursing studies exist |
| Under 18 | Never studied | Every published human study was in adults |
| Cancer, now or in the past | No data in people; a theoretical concern | The paragraph above; no study has included people with cancer |
| A blood thinner or a bleeding disorder | Not studied; a theoretical concern | Clotting-test changes in rats and dogs; the 2026 hamstring trial excludes both |
| Other medicines | No interaction data in people | It relaxed human artery tissue in the lab; an added effect with medicines that widen blood vessels is possible and untested |
| Athletes subject to drug testing | Prohibited at all times (see Sport, above) | Anti-doping labs have a urine test for it |
Product quality
The raw ingredient. Of the certificates of analysis (a lab’s report on a batch) that the FDA reviewed, most for the free base “only contain purity testing results,” and those for the acetate, the form HHS’s policy names, had “no testing results” for specified impurities, aggregates, microbial load or bacterial endotoxins (toxins from bacteria). HHS says it now has “a lot-specific certificate from an FDA-registered facility” with the results the FDA’s staff found lacking; its policy asks for such a certificate.
“Research use only” and other products sold directly to consumers. Of one seller’s injectable and nasal BPC-157 the FDA wrote in 2023 that the “products are not generally recognized as safe and effective.” The largest analysis we found is a 2026 preprint, not yet peer-reviewed, of 6,487 public test reports on peptides sold this way, sent in voluntarily by buyers and vendors. Across its 14 peptides, 41.6% to 71.1% failed the authors’ quality criteria, and endotoxin was found in 15% of the 243 samples tested for it. For BPC-157, 17 reports (3.5%) “did not contain the stated peptide.” That 3.5% is no reassurance: the authors call the reports “not a random or representative sample,” note that “Companies confident in their product quality may be more likely to submit samples,” and, with sterility, residual solvents and particulates untested, call the failure rates “a lower bound.”
Compounding pharmacies. HHS calls compounding under its conditions “a more controlled alternative.” It still depends on the pharmacy: one compounder that received an FDA warning letter was also cited for insanitary conditions, and it had made the BPC-157 used in the 2021 knee report.
What we make of it
This section is our judgment, not a finding.
What it is, on the evidence. BPC-157 is unproven and experimental. No controlled trial in people has shown a benefit by any route, and its safety in people is not established. Nobody should be told it has been shown to work.
Where a benefit is plausible. BPC-157 is not inert: labs with no Zagreb author, in several countries, broadly agree that it is biologically active, mainly on blood-vessel growth and nitric oxide. On the theory that new vessels and better blood flow support repair, an effect on healing is plausible. Plausible is not shown, and the caution above applies.
Where the claims outrun the evidence. “Proven,” “safe,” “works by mouth” and every stated dose claim more than anyone knows. The accurate version: active in animal and lab studies, almost untested in people.
What would have to be true. For a commonly promoted use, injections under the skin for a tendon or muscle injury: enough peptide reaches the injured tissue (in the knee report it was placed inside the joint), or sets off lasting signals, despite a half-life of minutes in animals; the benefit seen in rodents treated at the time of injury holds for human injuries weeks or months old; and the effect is large enough to show against placebo.
What we leave to our Medical Director. Whether BPC-157 has a place in anyone’s care, for whom, after what, with what monitoring and when to stop are his to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A placebo-controlled injury trial (NCT07437547). 120 adults with an MRI-confirmed hamstring strain receive BPC-157 or placebo under the skin daily for 14 days. Recruiting in Shenzhen, China, since February 2026 with an industry sponsor, it is the first such trial of injected BPC-157 for an injury; the registry estimates primary completion in February 2027.
- A rotator cuff trial (NCT07803250). A University of Arkansas pilot of daily under-the-skin injections for 90 days after shoulder surgery, due to start in January 2027.
- Two oral studies without results. A 2015 tablet trial in healthy volunteers (NCT02637284), registry status “UNKNOWN,” which the developers’ 2025 review describes as establishing safety while citing no data; and a gummy study by the product’s maker, with no comparison group (NCT07752381), completed in November 2025.
Common questions
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug, and the FDA’s 2026 review found no approved product containing it in any country. BPC-157 made by a compounding pharmacy is not FDA-approved either.
Can a doctor prescribe BPC-157?
From a pharmacy, BPC-157 is dispensed only on a prescription written for one patient, and it is not FDA-approved, so that prescription is for a compounded medicine. HHS’s draft policy on compounding single-ingredient BPC-157 acetate, described in the status section above, is not FDA approval.
Does BPC-157 work for tendon or gut healing?
It has not been shown to in people. Many rodent experiments report faster healing, but no study in people has measured tendon healing, and the one controlled gut trial, an enema for ulcerative colitis, did not show a difference from placebo.
What are the side effects of BPC-157?
Few have been reported, and too few people have been studied to know. Among about 88 people given it in published reports (five in the 2026 pilot), no serious adverse event was recorded, though that pilot noted injection-site reactions and one temporary liver-enzyme rise. Outside studies, the FDA’s public adverse-event database held 26 reports naming BPC-157 at its October 2026 update, 12 as a suspect product; none establishes a cause. A cancer risk has been raised in theory and has not been tested.
How often is BPC-157 taken?
No study has set a schedule. In published reports it was given anywhere from once to daily for two weeks, and in one pilot weekly for 26 weeks, depending on the route (see the dosing table). The daily schedules on clinic, pharmacy and seller pages are practice that no trial set. Your prescriber sets the schedule for you.
Sources
Show all 44 sourcesHide sources
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register (HHS), 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration, 2025.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026.
- World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency, 2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021.
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine, 2024.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025.
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health, 2026.
- PCO-02 – Safety and Pharmacokinetics Trial (NCT02637284). ClinicalTrials.gov, 2015.
- BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). ClinicalTrials.gov, 2026.
- Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250). ClinicalTrials.gov, 2026.
- A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (NCT07752381). ClinicalTrials.gov, 2026.
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica, 2026.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 2026.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals, 2025.
- Reply to Sikiric et al. … Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide”. Pharmaceuticals, 2025.
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals, 2025.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022.
- Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020.
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011.
- Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014.
- BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling, 2026.
- Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine, 2026.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
- The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. Journal of Dental Anesthesia and Pain Medicine, 2022.
- Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell, 2019.
- Antioxidants stimulate BACH1-dependent tumor angiogenesis. Journal of Clinical Investigation, 2023.
- Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Testing and Analysis, 2017.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org (not peer-reviewed), 2026.
- Pharmacologically active substance BPC, the process for its preparation and its use in the therapy (EP0432400A2). European Patent Office via Google Patents, 1991.
- New BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy (WO1998052973A1). WIPO via Google Patents, 1998.
- Warning Letter: Prescription Dispensing Laboratories, Inc. dba PD Labs, 579286. U.S. Food and Drug Administration, 2019.
- Warning Letter: Tailor Made Compounding LLC, 594743. U.S. Food and Drug Administration, 2020.
- Warning Letter: Predator Nutrition, MARCS-CMS 607136. U.S. Food and Drug Administration and Federal Trade Commission, 2020.
- Warning Letter: Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine, 615908. U.S. Food and Drug Administration, 2021.
- Warning Letter: Warrior Labz SARMS, MARCS-CMS 655280. U.S. Food and Drug Administration, 2023.
- July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration, 2026.
- K.A.R. 68-13-3, Nonsterile preparations. Kansas Secretary of State, 2018.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025.
- Adjunctive Weekly Subcutaneous Thymosin β4 and BPC-157 With Intensive Rehabilitation in Subacute AIS-B Thoracic Spinal Cord Injury: A 6-Month Open-Label Controlled Pilot Study. American Journal of Medical and Clinical Research & Reviews, 2026.
- openFDA drug adverse event (FAERS) data. U.S. Food and Drug Administration, 2026.
